Clinical blockade of PD1 and LAG3-potential mechanisms of action

被引：514

作者：

Nguyen, Linh T. ^{[1
]}

Ohashi, Pamela S. ^{[1
]}

机构：

[1] Princess Margaret Canc Ctr, Immune Therapy Program, Toronto, ON M5G 2M9, Canada

来源：

NATURE REVIEWS IMMUNOLOGY | 2015年 / 15卷 / 01期

关键词：

T-CELL-ACTIVATION; CHRONIC VIRAL-INFECTION; LYMPHOCYTE-ACTIVATION; PROGRAMMED DEATH-1; PHASE-I; ADVANCED MELANOMA; IMMUNE-RESPONSES; PD-1; EXPRESSION; B-CELLS; INHIBITORY RECEPTORS;

D O I：

10.1038/nri3790

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Dysfunctional T cells can render the immune system unable to eliminate infections and cancer. Therapeutic targeting of the surface receptors that inhibit T cell function has begun to show remarkable success in clinical trials. In this Review, we discuss the potential mechanisms of action of the clinical agents that target two of these receptors, programmed cell death protein 1 (PD1) and lymphocyte activation gene 3 protein (LAG3). We also suggest correlative studies that may define the predominant mechanisms of action and identify predictive biomarkers.

引用

页码：45 / 56

页数：12

共 125 条

[91] Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2 [J].

Shiratori, T ;

Miyatake, S ;

Ohno, H ;

Nakaseko, C ;

Isono, K ;

Bonifacino, JS ;

Saito, T .

IMMUNITY, 1997, 6 (05) :583-589

[92] The CD4-like molecule LAG-3, biology and therapeutic applications [J].

Sierro, Sophie ;

Romero, Pedro ;

Speiser, Daniel E. .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (01) :91-101

[93] Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells [J].

Spranger, Stefani ;

Spaapen, Robbert M. ;

Zha, Yuanyuan ;

Williams, Jason ;

Meng, Yuru ;

Ha, Thanh T. ;

Gajewski, Thomas F. .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (200)

[94] Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer [J].

Sznol, Mario ;

Chen, Lieping .

CLINICAL CANCER RESEARCH, 2013, 19 (05) :1021-1034

[95] Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4 [J].

Takahashi, T ;

Tagami, T ;

Yamazaki, S ;

Uede, T ;

Shimizu, J ;

Sakaguchi, N ;

Mak, TW ;

Sakaguchi, S .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (02) :303-309

[96] Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy [J].

Taube, Janis M. ;

Klein, Alison ;

Brahmer, Julie R. ;

Xu, Haiying ;

Pan, Xiaoyu ;

Kim, Jung H. ;

Chen, Lieping ;

Pardoll, Drew M. ;

Topalian, Suzanne L. ;

Anders, Robert A. .

CLINICAL CANCER RESEARCH, 2014, 20 (19) :5064-5074

[97] Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape [J].

Taube, Janis M. ;

Anders, Robert A. ;

Young, Geoffrey D. ;

Xu, Haiying ;

Sharma, Rajni ;

McMiller, Tracee L. ;

Chen, Shuming ;

Klein, Alison P. ;

Pardoll, Drew M. ;

Topalian, Suzanne L. ;

Chen, Lieping .

SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (127)

[98] PD-1 is a novel regulator of human B-cell activation [J].

Thibult, Marie-Laure ;

Mamessier, Emilie ;

Gertner-Dardenne, Julie ;

Pastor, Sonia ;

Just-Landi, Sylvaine ;

Xerri, Luc ;

Chetaille, Bruno ;

Olive, Daniel .

INTERNATIONAL IMMUNOLOGY, 2013, 25 (02) :129-+

[99] Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques [J].

Titanji, Kehmia ;

Velu, Vijayakumar ;

Chennareddi, Lakshmi ;

Vijay-Kumar, Matam ;

Gewirtz, Andrew T. ;

Freeman, Gordon J. ;

Amara, Rama R. .

JOURNAL OF CLINICAL INVESTIGATION, 2010, 120 (11) :3878-3890

[100] LOSS OF CTLA-4 LEADS TO MASSIVE LYMPHOPROLIFERATION AND FATAL MULTIORGAN TISSUE DESTRUCTION, REVEALING A CRITICAL NEGATIVE REGULATORY ROLE OF CTLA-4 [J].

TIVOL, EA ;

BORRIELLO, F ;

SCHWEITZER, AN ;

LYNCH, WP ;

BLUESTONE, JA ;

SHARPE, AH .

IMMUNITY, 1995, 3 (05) :541-547

← 4 5 6 7 8 9 10 11 12 13 →